- February 13, 2026– Upfront Proceeds of USD 200 Million, with Potential for up to USD 200 Million in Additional Proceeds – –…
- February 4, 2026– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER…
- January 7, 2026– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by…
